DELTA, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) has posted a loss of $52,380 for the year ended March 31, 2025 ($210,683 loss for the year ended March 31, 2024). The value ascribed to stock options granted during the year contributed to this small loss. Sales increased 4.9% to $9,673,002 this year compared to $9,219,948 for the year ended March 31, 2024.
The increase in revenue is the result of an increase in sales of wipe products and air-laid napkins and parent rolls, offset by a decrease in sales of personal hygiene, clinical, and other product categories. The addition of production staff, materials handling personnel and new equipment helped reduce the inefficiencies from the previous year.
Sales are expected to increase as we continue to manage inquiries from our current and potential customers from within Canada due to the uncertainties of tariffs from the USA. In addition, several new markets in the USA and Canada have been established in the food service industry involving major restaurant chains. The company continues to focus on this market segment, adding staff and new, high quality and competitive product lines.
The annual report and other information is available on the company’s website at www.westbond.ca and on SEDAR+ at www.sedarplus.ca.
For further information please contact:
Gennaro Magistrale
Chief Executive Officer, President and Director
WestBond Enterprises Corporation
101 – 7403 Progress Way, Delta, B.C. V4G 1E7
Tel: (604) 940-3939
Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the company’s intentions. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the company and the opinions and estimates of management as of the date of this press release, including the ability to sustain or develop markets and increase profitability. Although the company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, changes in operating performance, availability of and prices for raw materials, availability of trained labour, foreign currency exchange rate fluctuations, unexpected competition and other technical, market and economic factors. Although management of the company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Novartis receives approval for first malaria medicine for newborn babies and young infants - July 8, 2025
- Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 - July 8, 2025
- New WatchGuard Research Reveals 171% Increase in Total Unique Malware as Attackers Defy Traditional Defenses - July 8, 2025
